Clinical trial
Study to Evaluate the Efficacy and Safety of Single IV Doses of Onicit® (Palonosetron) 0.25 mg in the Prevention of Acute and Delayed Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in Colombia
NCT00684463 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study to Evaluate the Efficacy and Safety of Single IV Doses of Onicit® (Palonosetron) 0.25 mg in the Prevention of Acute and Delayed Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in Colombia
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 11, 2007
- Completion date
- February 22, 2008
- Enrollment
- 59 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.